These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33030272)

  • 1. Letter to the Editor: Retreatment Decision for Hepatitis B Flare in HBeAg-Negative Chronic Hepatitis B.
    Kumar K; Dixit I
    Hepatology; 2021 May; 73(5):2081-2082. PubMed ID: 33030272
    [No Abstract]   [Full Text] [Related]  

  • 2. HBsAg Kinetics in Retreatment Decision for Off-Therapy Hepatitis B Flare in HBeAg-Negative Patients.
    Liaw YF; Jeng WJ; Chang ML
    Gastroenterology; 2018 Jun; 154(8):2280-2281. PubMed ID: 29746811
    [No Abstract]   [Full Text] [Related]  

  • 3. Re-treatment for severe hepatitis flare in HBeAg-negative chronic hepatitis B: An appraisal with combined HBsAg/ALT kinetics.
    Chien RN; Liaw YF
    J Viral Hepat; 2020 May; 27(5):544-547. PubMed ID: 31868280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
    Deng R; Wang Z; Liu Y; Sun J
    Hepatology; 2024 Apr; 79(4):E107-E108. PubMed ID: 37906598
    [No Abstract]   [Full Text] [Related]  

  • 5. Durability of serologic response after lamivudine treatment of chronic hepatitis B.
    Dienstag JL; Cianciara J; Karayalcin S; Kowdley KV; Willems B; Plisek S; Woessner M; Gardner S; Schiff E
    Hepatology; 2003 Apr; 37(4):748-55. PubMed ID: 12668966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reply to Letter to the Editor: Retreatment Decision for Hepatitis B Flare.
    Liaw YF
    Hepatology; 2021 May; 73(5):2082-2083. PubMed ID: 33020909
    [No Abstract]   [Full Text] [Related]  

  • 7. The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B.
    Wong GL; Chan HL; Yuen BW; Tse YK; Luk HW; Yip TC; Hui VW; Liang LY; Lee HW; Lui GC; Wong VW
    Liver Int; 2020 Mar; 40(3):549-557. PubMed ID: 31845462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can we stop nucleoside analogues before HBsAg loss?
    Papatheodoridi M; Papatheodoridis G
    J Viral Hepat; 2019 Aug; 26(8):936-941. PubMed ID: 30803099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.
    Dienstag JL; Schiff ER; Mitchell M; Casey DE; Gitlin N; Lissoos T; Gelb LD; Condreay L; Crowther L; Rubin M; Brown N
    Hepatology; 1999 Oct; 30(4):1082-7. PubMed ID: 10498663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early virological response predicts outcome during extended lamivudine retreatment in patients with chronic hepatitis B who relapsed after initial HBeAg responses.
    Jang JW; Bae SH; Choi JY; Kim CW; Han NI; Han JY; Choi SW; Yoon SK; Chung KW; Sun HS
    J Gastroenterol Hepatol; 2006 Feb; 21(2):384-91. PubMed ID: 16509863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B.
    Papatheodoridi M; Hadziyannis E; Berby F; Zachou K; Testoni B; Rigopoulou E; Gatselis NK; Lyberopoulou A; Vlachogiannakos I; Manolakopoulos S; Dalekos GN; Zoulim F; Papatheodoridis GV
    J Viral Hepat; 2020 Feb; 27(2):118-126. PubMed ID: 31562748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
    Papatheodoridis GV; Rigopoulou EI; Papatheodoridi M; Zachou K; Xourafas V; Gatselis N; Hadziyannis E; Vlachogiannakos J; Manolakopoulos S; Dalekos GN
    Antivir Ther; 2018; 23(8):677-685. PubMed ID: 30044765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical outcome of HBeAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues.
    Manolakopoulos S; Kranidioti H; Kourikou A; Deutsch MM; Triantos C; Tsolias C; Manesis EK; Mathou N; Alexopoulou A; Hadziyannis E; Papatheodoridis G
    Liver Int; 2021 Jan; 41(1):48-57. PubMed ID: 33373114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients.
    Chen CH; Hung CH; Wang JH; Lu SN; Hu TH; Lee CM
    Clin Microbiol Infect; 2018 Sep; 24(9):997-1003. PubMed ID: 29288020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non-cirrhotic HBeAg-positive chronic hepatitis B.
    Chen H; Ding X; Liao G; Xia M; Ren Z; Fan R; Peng J
    J Viral Hepat; 2021 Aug; 28(8):1121-1129. PubMed ID: 33899998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical characteristics of hepatic flare and efficacy of antiviral therapy in pregnant women with chronic hepatitis B virus infection].
    Ding Y; Sheng QJ; Zhang C; Wu YY; Yuan SY; Xia TT; An ZY; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2019 Feb; 27(2):106-111. PubMed ID: 30818914
    [No Abstract]   [Full Text] [Related]  

  • 17. The impact of hepatitis flare on HBeAg loss was effective mainly in the first year of Nucleot(s)ide therapy in chronic hepatitis B.
    Peng CW; Jeng WJ; Chien RN; Liaw YF
    J Viral Hepat; 2021 Mar; 28(3):475-483. PubMed ID: 33274536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stopping Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B.
    Liaw YF
    Gastroenterology; 2020 Sep; 159(3):1186. PubMed ID: 32433984
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of seasonal variation on the clinical course of chronic hepatitis B.
    Zhang SJ; Chen ZX; Jiang KP; Wu WK; Zhang CY; Gu YL
    J Gastroenterol; 2006 Nov; 41(11):1107-15. PubMed ID: 17160522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy.
    Chen CH; Hu TH; Wang JH; Lai HC; Hung CH; Lu SN; Peng CY
    Hepatol Int; 2020 May; 14(3):317-325. PubMed ID: 31650509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.